For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker
             analysis

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and
             at least 1 lesion accessible for biopsy

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Radiographically documented progressive disease on or after the most recent therapy

          -  Received standard-of-care therapies, including an available programmed death
             (ligand)-1 inhibitor known to be effective in the tumor type for which they are being
             evaluated

          -  Parts 1A, 1B, and 2A: Advanced or metastatic non-small cell lung cancer, squamous cell
             carcinoma of head and neck, microsatellite stable colorectal cancer, gastric/
             gastroesophageal junction adenocarcinoma, or cervical cancer, and have received, be
             refractory to, not be a candidate for, or be intolerant of existing therapies known to
             provide clinical benefit for the condition of the participant

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Primary central nervous system (CNS) malignancy

          -  Untreated CNS metastases

          -  Leptomeningeal metastases

          -  Concurrent malignancy requiring treatment or history of prior malignancy active within
             2 years prior to the first dose of study treatment

          -  Active, known, or suspected autoimmune disease

          -  Condition requiring systemic treatment with either corticosteroids within 14 days or
             other immunosuppressive medications within 30 days of the first dose of study
             treatment

          -  Prior organ or tissue allograft

          -  Uncontrolled or significant cardiovascular disease

          -  Major surgery within 4 weeks of study drug administration

          -  History of or with active interstitial lung disease or pulmonary fibrosis

        Other protocol-defined inclusion/exclusion criteria apply